The Greulich and Pyle Atlas is used to estimate the age of children and adolescents. This systematic review summarizes scientific knowledge of the agreement between the skeletal age of the Greulich and Dempyle Atlas (hereafter the age of the GP skeleton) and chronological age. A total of 17 studies met our criteria. 13 studies presented results for age of the GP skeleton from chronological age, 2 results for chronological age from GP age and 2 were data sets that we used to represent both types of results. These two approaches are not comparable, so we did two separate analyses. The difference between the skeletal age of the family physician and chronological age was rarely greater than one year for each age group. Studies that have represented the distribution of chronological age from gp age are most relevant when using the Greulich and Pyle atlases to estimate age. Here, we did not do a meta-analysis, because the results of three of the four studies were so influenced by the phenomenon of the microrema of age that we do not trust the results. We estimated that only one study was conducted in such a way as to adequately describe the method`s ability to estimate age.
(New version released July 3, 2017. Updated analyses based on corrected and verified data. The amendments did not influence the conclusion.) “This agreement with Catalent is an important strategic step for Bone Therapeutics and the result of our ongoing efforts to optimize our business,” said Miguel Forte, CEO of Bone Therapeutics. “The integration of our manufacturing subsidiary in Catalent, one of the leading manufacturers of contracted products in the field of cell therapy, significantly improves our operational flexibility. It enables Bone Therapeutics to maximize the efficient use of our production facilities by combining the production site and specialized operators with Catalent`s global network of clinical and commercial production facilities and ensuring the level of employment at the production site. This will ensure allOB`s most efficient global production. In addition, we can continue to focus on our core business: the development of innovative cell-based treatments for diseases with high medical demand. For requests from French media and investors:NewCap Investor Relations – Financial CommunicationsPierre Laurent, Louis-Victor Delouvrier and Arthur RouilléTel: `33 (0)1 44 71 94 email@example.com The Bonn Agreement (officially the agreement on interim arrangements in Afghanistan until the re-establishment of permanent state institutions) was the first set of agreements adopted on 5 December 2001 aimed at re-establishing the State of Afghanistan after the United States.